157 related articles for article (PubMed ID: 17994386)
1. Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient.
Sheikh-Taha M; Koussa S; Inati A; Taher A
Hemoglobin; 2007; 31(4):499-501. PubMed ID: 17994386
[TBL] [Abstract][Full Text] [Related]
2. Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count.
El-Beshlawy AM; El-Alfy MS; Sari TT; Chan LL; Tricta F
Eur J Haematol; 2014 Apr; 92(4):337-40. PubMed ID: 24330079
[TBL] [Abstract][Full Text] [Related]
3. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients.
Ceci A; Baiardi P; Felisi M; Cappellini MD; Carnelli V; De Sanctis V; Galanello R; Maggio A; Masera G; Piga A; Schettini F; Stefàno I; Tricta F
Br J Haematol; 2002 Jul; 118(1):330-6. PubMed ID: 12100170
[TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
5. A multi-center safety trial of the oral iron chelator deferiprone.
Cohen A; Galanello R; Piga A; Vullo C; Tricta F
Ann N Y Acad Sci; 1998 Jun; 850():223-6. PubMed ID: 9668543
[TBL] [Abstract][Full Text] [Related]
6. A Case of Fatal Agranulocytosis That Developed in a Patient with β-Thalassemia Major Treated with Deferiprone.
Mainou M; Kotsiafti A; Klonizakis P; Soulountsi V; Apostolou C; Psarras K; Vlachaki E
Hemoglobin; 2016 Nov; 40(6):435-437. PubMed ID: 28361596
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
8. Deferiprone-induced seizures in a patient with β-thalassemia major.
Mallat NS; Beydoun A; Musallam KM; Koussa S; Taher AT
Blood Cells Mol Dis; 2013 Aug; 51(2):94-5. PubMed ID: 23587452
[No Abstract] [Full Text] [Related]
9. Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis.
Tewari S; Tewari S; Sharma RK; Abrol P; Sen R
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Oct; 108(4):e13-9. PubMed ID: 19778731
[TBL] [Abstract][Full Text] [Related]
10. Deferiprone chelation therapy for thalassemia major.
Galanello R; Campus S
Acta Haematol; 2009; 122(2-3):155-64. PubMed ID: 19907153
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Wu KH; Chang JS; Tsai CH; Peng CT
Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011
[TBL] [Abstract][Full Text] [Related]
12. Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia.
Jamuar SS; Lai AH; Tan AM; Chan MY; Tan ES; Ng IS
J Paediatr Child Health; 2011 Nov; 47(11):812-7. PubMed ID: 21902752
[TBL] [Abstract][Full Text] [Related]
13. Deferiprone (L1) associated neutropenia in beta thalassemia major: an Indian experience.
Pati HP; Choudhry VP
Eur J Haematol; 1999 Oct; 63(4):267-8. PubMed ID: 10530416
[No Abstract] [Full Text] [Related]
14. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
[TBL] [Abstract][Full Text] [Related]
15. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
[TBL] [Abstract][Full Text] [Related]
16. Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.
Botzenhardt S; Sing CW; Wong IC; Chan GC; Wong LY; Felisi M; Rascher W; Ceci A; Neubert A
Curr Drug Saf; 2016; 11(2):137-44. PubMed ID: 26419768
[TBL] [Abstract][Full Text] [Related]
17. Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.
Elalfy M; Wali YA; Qari M; Al Damanhouri G; Al-Tonbary Y; Yazman D; Al Hawsawi Z; Karakas Z; Kilinc Y; Yesilipek MA; Badr M; Elsafy U; Salama M; Abdel Rahman Y; Shebl S; Stilman A; Toiber Temin N; Tricta F
Pediatr Blood Cancer; 2014 May; 61(5):879-84. PubMed ID: 24376176
[TBL] [Abstract][Full Text] [Related]
18. Isolated thrombocytopenia associated with hydroxyurea/deferiprone (L1) therapy in a sickle beta thalassemia patient.
Sheikh-Taha M; Koussa S; Taher A
Haematologica; 2006 Jun; 91(6 Suppl):ECR25. PubMed ID: 16785128
[No Abstract] [Full Text] [Related]
19. Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone.
Pontikoglou C; Papadaki HA
Hemoglobin; 2010 Jun; 34(3):291-304. PubMed ID: 20524819
[TBL] [Abstract][Full Text] [Related]
20. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Wu SF; Peng CT; Wu KH; Tsai CH
Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
